Kallistatin as a New and Reliable Biomarker for the Diagnosis of Liver Cirrhosis
Olfat Saif Elmasih Azmy;
Abstract
The human liver is the largest single organ in the body and consists of parenchymal cells, which metabolize, detoxify, synthesize, and store nutrients. Normal functioning of these cells depends on their proper organization.Cirrhosis of the liver is a consequence of chronic liver disease characterized by irreversible replacement of a liver tissue by a fibrotic scar tissue as well as regenerative nodules, leading to progressive loss of liver function.
Most patients with cirrhosis die from one or more clinical complications including ascites, hepatic encephalopathy and variceal hemorrhage. Many of liver disease-related deaths that occur each year worldwide are directly attributable to cirrhosis.
It is important to identify reliable biomarkers for the early detection of liver disease as recent evidence from animal studies and human clinical observations indicated that even advanced fibrosis can be reversed.
The liver represents the major site of synthesis and secretion of kallistatin.
Kallistatin, an endogenous human serine proteinase inhibitor, was originally known as a tissue kallikrein inhibitor,it has vasodilatory, anti-angiogenic, anti-inflammatory, anti-tumor and anti-oxidant effects.
The focus of this study was to determine the value of kallistatinin patients with liver cirrhosis and heptocellular carcinoma and to determine if serum kallistatin levels could be used as adiagnostic indicator of hepatic health status especially human liver cirrhosis.
In the present study, fifty subjects were included and classified into three groups; group I included twenty patients with liver cirrhosis. Group II included twenty patients with heptocellualr carcinoma . Group III included ten healthy persons as a control group.
The results in the current study revealed that there was highly significant decrease of kallistatin level in liver cirrhosis patients and HCC patients compared to control group.These findings pointed to the value of kallistain as a new biomarker for diagnosis of liver cirrhosis.
Conclusion: kallistatin was significantly decreased in liver cirrhosis patients.Therefore, it has the potential to be a new biomarker for diagnosis of liver cirrhosis.
Most patients with cirrhosis die from one or more clinical complications including ascites, hepatic encephalopathy and variceal hemorrhage. Many of liver disease-related deaths that occur each year worldwide are directly attributable to cirrhosis.
It is important to identify reliable biomarkers for the early detection of liver disease as recent evidence from animal studies and human clinical observations indicated that even advanced fibrosis can be reversed.
The liver represents the major site of synthesis and secretion of kallistatin.
Kallistatin, an endogenous human serine proteinase inhibitor, was originally known as a tissue kallikrein inhibitor,it has vasodilatory, anti-angiogenic, anti-inflammatory, anti-tumor and anti-oxidant effects.
The focus of this study was to determine the value of kallistatinin patients with liver cirrhosis and heptocellular carcinoma and to determine if serum kallistatin levels could be used as adiagnostic indicator of hepatic health status especially human liver cirrhosis.
In the present study, fifty subjects were included and classified into three groups; group I included twenty patients with liver cirrhosis. Group II included twenty patients with heptocellualr carcinoma . Group III included ten healthy persons as a control group.
The results in the current study revealed that there was highly significant decrease of kallistatin level in liver cirrhosis patients and HCC patients compared to control group.These findings pointed to the value of kallistain as a new biomarker for diagnosis of liver cirrhosis.
Conclusion: kallistatin was significantly decreased in liver cirrhosis patients.Therefore, it has the potential to be a new biomarker for diagnosis of liver cirrhosis.
Other data
| Title | Kallistatin as a New and Reliable Biomarker for the Diagnosis of Liver Cirrhosis | Other Titles | قياس مستوى الكاليستاتين فى الدم كوسيلة لتشخيص تلـيـف الكبد | Authors | Olfat Saif Elmasih Azmy | Issue Date | 2017 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.